Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma

Kyrollis Attalla; Stanley Weng; Martin H. Voss; A. Ari Hakimi

doi:10.1016/j.ucl.2020.04.002

Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma

Kyrollis Attalla, Stanley Weng, Martin H. Voss, A. Ari Hakimi

Research output: Contribution to journal › Review article › peer-review

39 Scopus citations

Abstract

In the preceding two decades, several milestones have been reached in the management of patients with metastatic renal cell carcinoma (mRCC), including the development of novel targeted agents paralleling an increased understanding of the molecular biology of this disease process. Recently, a renewed enthusiasm for immunotherapy in the form of immune checkpoint blockade has resulted in significant strides in the treatment of mRCC. Despite these advances, treatment remains challenging for clinicians, and only modest survival benefits are observed with current treatment paradigms. The risk-stratification tools and investigated predictive and prognostic biomarkers in patients with mRCC are detailed in this review.

Original language	English
Pages (from-to)	293-303
Number of pages	11
Journal	Urologic Clinics of North America
Volume	47
Issue number	3
DOIs	https://doi.org/10.1016/j.ucl.2020.04.002
State	Published - Aug 2020
Externally published	Yes

Keywords

Immunotherapy
Metastatic renal cell carcinoma
Predictive biomarker
Prognostic biomarker
Risk assessment
Targeted therapy

Access to Document

10.1016/j.ucl.2020.04.002

Cite this

@article{410d74e3179742de93287c5e4fbc65fa,

title = "Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma",

abstract = "In the preceding two decades, several milestones have been reached in the management of patients with metastatic renal cell carcinoma (mRCC), including the development of novel targeted agents paralleling an increased understanding of the molecular biology of this disease process. Recently, a renewed enthusiasm for immunotherapy in the form of immune checkpoint blockade has resulted in significant strides in the treatment of mRCC. Despite these advances, treatment remains challenging for clinicians, and only modest survival benefits are observed with current treatment paradigms. The risk-stratification tools and investigated predictive and prognostic biomarkers in patients with mRCC are detailed in this review.",

keywords = "Immunotherapy, Metastatic renal cell carcinoma, Predictive biomarker, Prognostic biomarker, Risk assessment, Targeted therapy",

author = "Kyrollis Attalla and Stanley Weng and Voss, {Martin H.} and Hakimi, {A. Ari}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = aug,

doi = "10.1016/j.ucl.2020.04.002",

language = "English",

volume = "47",

pages = "293--303",

journal = "Urologic Clinics of North America",

issn = "0094-0143",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma

AU - Attalla, Kyrollis

AU - Weng, Stanley

AU - Voss, Martin H.

AU - Hakimi, A. Ari

PY - 2020/8

Y1 - 2020/8

N2 - In the preceding two decades, several milestones have been reached in the management of patients with metastatic renal cell carcinoma (mRCC), including the development of novel targeted agents paralleling an increased understanding of the molecular biology of this disease process. Recently, a renewed enthusiasm for immunotherapy in the form of immune checkpoint blockade has resulted in significant strides in the treatment of mRCC. Despite these advances, treatment remains challenging for clinicians, and only modest survival benefits are observed with current treatment paradigms. The risk-stratification tools and investigated predictive and prognostic biomarkers in patients with mRCC are detailed in this review.

AB - In the preceding two decades, several milestones have been reached in the management of patients with metastatic renal cell carcinoma (mRCC), including the development of novel targeted agents paralleling an increased understanding of the molecular biology of this disease process. Recently, a renewed enthusiasm for immunotherapy in the form of immune checkpoint blockade has resulted in significant strides in the treatment of mRCC. Despite these advances, treatment remains challenging for clinicians, and only modest survival benefits are observed with current treatment paradigms. The risk-stratification tools and investigated predictive and prognostic biomarkers in patients with mRCC are detailed in this review.

KW - Immunotherapy

KW - Metastatic renal cell carcinoma

KW - Predictive biomarker

KW - Prognostic biomarker

KW - Risk assessment

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85086397723&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2020.04.002

DO - 10.1016/j.ucl.2020.04.002

M3 - Review article

C2 - 32600532

AN - SCOPUS:85086397723

SN - 0094-0143

VL - 47

SP - 293

EP - 303

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

IS - 3

ER -

Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this